Back to Search
Start Over
Anti-β<SUB>2</SUB>-glycoprotein I antibodies in children with atopic dermatitis
- Source :
- International Immunology; July 2002, Vol. 14 Issue: 7 p823-830, 8p
- Publication Year :
- 2002
-
Abstract
- β<SUB>2</SUB>-Glycoprotein I (β<SUB>2</SUB>GPI) appears to be the major antigen for antiphospholipid antibodies (aPL) in patients with antiphospholipid syndrome (APS). In early infancy, virtually all children initiate transient immune response to non-pathogenic nutritional antigens, which fails to terminate in children with atopic diseases. To examine the possibility that a prolonged immune response to β<SUB>2</SUB>GPI could also spread to the human protein, antibodies against human β<SUB>2</SUB>GPI (anti-β<SUB>2</SUB>GPI) were determined in 93 randomly selected children with different allergic diseases. A high frequency (42%) of IgG anti-β<SUB>2</SUB>GPI was found in children with atopic dermatitis (AD), but not in those with other allergic diseases. Anti-β<SUB>2</SUB>GPI in children with AD were exclusively of the IgG1 subclass and bound to bovine β<SUB>2</SUB>GPI as well, but not to either β<SUB>2</SUB>GPI combined with the phospholipid cardiolipin. The epitopes were identified in domain V of β<SUB>2</SUB>GPI and the antibody binding was abolished upon the specific proteolytic cleavage of the phospholipid-binding C-terminal loop in domain V of β<SUB>2</SUB>GPI. These results indicated that the epitopes for anti-β<SUB>2</SUB>GPI in children with AD most likely resided in close vicinity of the phospholipid-binding site of β<SUB>2</SUB>GPI. The epitopic difference from anti-β<SUB>2</SUB>GPI in APS may explain presumed non-thrombogenicity of anti-β<SUB>2</SUB>GPI in children with AD.
Details
- Language :
- English
- ISSN :
- 09538178 and 14602377
- Volume :
- 14
- Issue :
- 7
- Database :
- Supplemental Index
- Journal :
- International Immunology
- Publication Type :
- Periodical
- Accession number :
- ejs4228741